Device-based LAAC noninferior to NOAC therapy in AF patients
In the prevention of stroke in patients with atrial fibrillation (AF), device-based left atrial appendage closure (LAAC) compares favourably with non–vitamin K antagonist oral anticoagulant (NOAC) therapy, with the added advantage of reduced non–procedure-related bleeding, according to the CHAMPION-AF trial.
